| 1 |
Reusch U, Duell J, Ellwanger K, Herbrecht C, Knackmuss SH, Fucek I, Eser M, McAleese F, Molkenthin V, Le Gall F, et al. A tetravalent bispecific TandAb (CD19/CD3), AFM11, eciently recruits T cells for the potent lysis of CD19+tumor cells. MAbs. 2015. 7: 584-604.
DOI
|
| 2 |
Ridgway JB, Presta LG, Carter P. 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. Des. Sel. 1996. 9: 617-621.
DOI
|
| 3 |
Rodgers KR, Chou RC. Therapeutic monoclonal antibodies and derivatives: Historical perspectives and future directions. Biotechnol Adv. 2016. 34: 1149-1158.
DOI
|
| 4 |
Rothe A, Hosse RJ, Power BE. Ribosome display for improved biotherapeutic molecules. Expert Opin Biol Ther. 2006. 6: 177-187.
DOI
|
| 5 |
Seo KW, Seo SK, Ryu SL, Uhm JH, Baek JH, Kim BC, Lee BY. Trend in the development of antibody medicine. Specialty data collection in recombinant medicine Book 6. Dec. 2015. Advanced Therapy Products Research Team. National Institute of Food and Drug Safety Evaluation. Korea Mistry of Food Drug Safety. Korea.
|
| 6 |
Schaefer W, Regula JT, Bahner M, Schanzer J, Croasdale R, Durr H, Gassner C, Georges G, Kettenberger H, Imhof-Jung S, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci USA. 2011. 108: 11187-11192.
DOI
|
| 7 |
Shi M, Su RJ, Parmar KP, Chaudhry R, Sun K, Rao J, Chen M. CD123: A Novel Biomarker for Diagnosis and Treatment of Leukemia. Cardiovasc Hematol Disord Drug Targets. 2019. 19: 195-204.
DOI
|
| 8 |
Shim H. Bispecific Antibodies and Antibody-Drug Conjugates for Cancer Therapy: Technological Considerations. Biomolecules. 2020. 10: 360.
DOI
|
| 9 |
Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science. 1985. 228: 1315-1317.
DOI
|
| 10 |
2019 Pharmaceutical Industry DATABOOK Statistic Information, 2019. KPBMA (Korea Pharmaceutical and Bio-Pharma Manufacturers Association). Korea.
|
| 11 |
Abclon. homepage. 2020. http://www.abclon.com/the/therapeutic_-antibody02.asp
|
| 12 |
ABLBio. homepage. 2020. https://www.ablbio.com/kr/company/pipeline01
|
| 13 |
Almagro JC, Fransson J. Humanization of antibodies. Front Biosci. 2008. 13: 1619-1633.
|
| 14 |
Brinkmann U, Kontermann RE. The making of bispecific antibodies. MAbs. 2017. 9: 182-212.
DOI
|
| 15 |
Sung DW. Trend and prospect in global biomedicine industry. Industry and Economy Team. Overseas Economy Research Center. The Export Import Bank of Korea. 2019. vol. 2019-Issue-20. Korea.
|
| 16 |
Spiess C, Merchant M, Huang A, Zheng Z, Yang NY, Peng J, Ellerman D, Shatz W, Reilly D, Yansura DG, Scheer JM. Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies. Nat Biotechnol. 2013. 31: 753-758.
DOI
|
| 17 |
Staerz UD, Bevan MJ. Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity. Proc Natl Acad Sci USA. 1986. 83: 1453-1457.
DOI
|
| 18 |
Strohl WR. Current progress in innovative engineered antibodies. Protein Cell. 2018. 9: 86-120.
DOI
|
| 19 |
Waldmann H. Human Monoclonal Antibodies: The Benefits of Humanization. Methods Mol Biol. 2019. 1904: 1-10.
DOI
|
| 20 |
Wang Q, Chen Y, Park J, Liu X, Hu Y, Wang T, McFarland K, Betenbaugh MJ. Design and Production of Bispecific Antibodies. Antibodies (Basel). 2019. 8: 43.
DOI
|
| 21 |
Wu X, Sereno AJ, Huang F, Lewis SM, Lieu RL, Weldon C, Torres C, Fine C, Batt MA, Fitchett JR, Glasebrook AL, Kuhlman B, Demarest SJ. Fab-based bispecific antibody formats with robust biophysical properties and biological activity. MAbs. 2015. 7: 470-482.
DOI
|
| 22 |
ClinicalTrails,gov. homepage. 2020. https://www.clinicaltrials.gov/ct2/home
|
| 23 |
Wu C, Ying H, Grinnell C, Bryant S, Miller R, Clabbers A, Bose S, McCarthy D, Zhu RR, Santora L, et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol. 2007. 25: 1290-1297.
DOI
|
| 24 |
YBiologics. Homepage. 2020. http://www.ybiologics.com/kor/pipeline/index.php?gubun=3
|
| 25 |
Zhang J, Yi J, Zhou P. Development of bispecific antibodies in China: overview and prospect. Antibody Therapeutics. 2020. 3: 126-145
DOI
|
| 26 |
Cha SH. Trend in the development of therapeutic antibodies II. Bispecific antibody. Jun 2011. The News Letters of the Korea Association of Biochemistry and Molecular Biology. Korea.
|
| 27 |
CKD Pharma. homepage. 2020. http://www.ckdpharm.com/research/project.do
|
| 28 |
Creative Biolabs. homepage. 2020 Aug. https://www.creativebiolabs.com/bsab/
|
| 29 |
Eutilex. homepage. 2020. http://www.eutilex.com/sub3/sub1.php
|
| 30 |
DiMasi N, Fleming R, Wu H, Gao C. Molecular engineering strategies and methods for the expression and purification of IgG1-based bispecific bivalent antibodies. Methods. 2019. 154: 77-86.
DOI
|
| 31 |
EvaluatePharma World Preview 2019, Outlook to 2024. June 04, 2019. https://www.evaluate.com/thought-leadership/pharma/evaluatepharma-world-preview-2019-outlook-2024
|
| 32 |
Frenzel A, Schirrmann T, Hust M. Phage display-derived human antibodies in clinical development and therapy. MAbs. 2016. 8: 1177-1194.
DOI
|
| 33 |
Gul N, van Egmond M. Antibody-dependent phagocytosis of tumor cells by macrophages: A potent effector mechanism of monoclonal antibody therapy of cancer. Cancer Res. 2015. 75: 5008-5013.
DOI
|
| 34 |
Ha JH, Kim JE, Kim YS. Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins. Front Immunol. 2016. 7: article 394.
|
| 35 |
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011. 144: 646-674.
DOI
|
| 36 |
Hanes J, Pluckthun A. In vitro selection and evolution of functional proteins by using ribosome display. Proc Natl Acad Sci U S A. 1997. 94: 4937-4942.
DOI
|
| 37 |
Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975. 256: 495-497.
DOI
|
| 38 |
Husain B. Ellerman D. Expanding the boundaries of biotherapeutics with bispecific antibodies. BioDrugs. 2018. 32: 441-464.
DOI
|
| 39 |
Kim SW, Lee EK. Trend in the global antibody medicine market and technology development. Bioeconomy Report. Korea Bioeconomy Research Center. Korea Biomedicine Industry Association. Jun 26 2020. Korea
|
| 40 |
Kipriyanov SM, Moldenhauer G, Schuhmacher J, Cochlovius B, Von Der Lieth CW, Matys E, Little M. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. J Mol Boil. 1999. 293: 41-56.
DOI
|
| 41 |
Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019. 18: 585-608.
DOI
|
| 42 |
Lu RM, Hwang YC, Liu IJ, Lee CC, Tsai HZ, Li HJ, Wu HC. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020. 27: 1-30.
DOI
|
| 43 |
Mamidi S, Hone S, Kirschfink M. The complement system in cancer: Ambivalence between tumour destruction and promotion. Immunobiology. 2017. 222: 45-54.
DOI
|
| 44 |
Nisonoff A, Wissler FC, Lipman LN. Properties of the major component of a peptic digest of rabbit antibody. Science. 1960. 132: 1770-1771.
DOI
|
| 45 |
Ochoa MC, Minute L, Rodriguez I, Garasa S, Perez-Ruiz E, Inoges S, Melero I, Berraondo P. Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells. Immunol Cell Biol. 2017. 95: 347-355.
DOI
|
| 46 |
Hanmi Pharma. homepage. 2020. http://www.hanmi.co.kr/hanmi/handler/Rnd-Pentambody
|
| 47 |
Pharmabcine. homepage. 2020. http://www.pharmabcine.com/sub02/sub02.php
|
webmaster
